RaymondsIndex

On September 2, 2026, at its fifteenth regular meeting, Korea's Securities and Futures Commission referred an investor-relations officer at a KOSDAQ-listed company to prosecutors on suspicion of trading on material non-public information. The facts, as the regulator described them, are compact. The officer, working in IR, obtained the topline result of a Phase 1 clinical trial and news of a signed drug-licensing agreement before either became public. Between March and June 2024, shares in the company were bought through an account held in another person's name. The gain was approximately 20 million won. The officer also failed to file the ownership report that Korean law requires of insiders. Under the Financial Investment Services and Capital Markets Act, an insider who uses material non-public information in trading faces imprisonment of at least one year, or a fine of up to six times the unlawful gain, with an administrative penalty of up to twice the gain also available. ...

On September 1, GoPro announced it was being acquired. Starman Optical, a privately held maker of optical transceivers, will take roughly 90% of the company in a $285 million deal. Existing shareholders receive $1.14 per share in cash and retain about 10% of the combined business, which stays listed on Nasdaq; closing is expected by the end of 2026, subject to regulatory and shareholder approval. GoPro's roughly $92 million of outstanding debt is repaid in full at closing. The context matters more than the headline. In an August filing, GoPro told regulators that years of operating losses and deteriorating finances had raised "substantial doubt" about whether it would have enough cash to pay its bills and debts over the next year. Second-quarter revenue came in at $105 million, down 31% from a year earlier, alongside a $51 million net loss. Quarterly revenue had peaked above $630 million in the final quarter of 2014, shortly after the company went public. Back in April,...

The filing On 30 June 2026, a KOSDAQ-listed industrial firm, VitzroSys Co., Ltd. (054220), filed a material event report announcing the sale of a convertible bond it already owned. The instrument was its own 15th series — an unsecured, privately placed convertible issued 24 October 2024, maturing 24 October 2027, with a face total of KRW 3,000,000,000. The company had bought KRW 2,500,000,000 of that face value back from bondholders before maturity, in three tranches — 24 October 2025, 28 November 2025 and 27 April 2026 — paying KRW 2,558,919,830. The filing describes the mechanism plainly: acquisition of the bond before maturity by agreement with the bondholders. It then sold the same paper back out for KRW 2,500,000,000. Stated purpose: securing operating funds and the like. Price basis: determined by negotiation with the buyer, taking the company's overall circumstances into account. On the stated figures, the company paid KRW 58,919,830 more to retrieve the bond than it rec...

The standard picture of a capital-inefficient company is easy to draw. It stops investing. Revenue flattens or falls. Assets sit idle while management waits for a cycle that does not turn. Every screen in the market is built to catch that shape. A KOSDAQ filing from 31 August draws a different one. TKG Aegang, a maker of piping materials, saw its controlling shareholder TKG Taekwang file a tender offer statement that day — the second this year — as part of a move to take the company private. What sits underneath that filing is the more interesting document. In the FY2025 annual report, revenue rose from 58.41bn won to 64.73bn, an increase of 10.8%. Operating loss widened from 3.69bn to 10.84bn. Net loss widened from 1.93bn to 11.53bn. Operating cash flow ran at negative 1.0bn. Investing outflows reached 26.87bn. Financing inflows reached 29.68bn. And receivables climbed from 10.28bn to 14.77bn — a rise of 43.7%, more than four times the growth rate of the sales that produced them. ...

Between August 12 and August 20, the Korea Exchange attached the "administrative issue" designation to 43 KOSPI and KOSDAQ companies. Thirty-six came on a single day. Thirty-two were tagged for trading below ₩1,000 for thirty consecutive sessions, fifteen for falling short of the market-capitalization floor — ₩20bn on KOSDAQ, ₩30bn on KOSPI — and four for both at once. The rules that produced this took effect on July 1. A company that fails to clear the threshold for 45 consecutive sessions within the following 90 is delisted. The policy has a name in Korean: dasan-dasa — many births, many deaths. List innovators quickly, remove failures quickly. When the Financial Services Commission and the exchange simulated the reform in February, they projected as many as 220 companies exiting. The escape route that leads back inside Faced with a price floor, a company has one obvious lever: shrink the share count and multiply the price. Hanwha Investment & Securities counted 27...

On 14 August 2026, Korea's semi-annual reporting deadline closed. What surfaced afterward was not a new set of failing companies. It was a new set of observed ones. Ten bio and healthcare issuers received a disclaimer of opinion on their half-year statements — among them Kainos Medicine, Cellumed, Syntekabio, Enzychem Lifesciences, Rolling Stone, Eutilex, Celestra, EOFlow, Olipass and Korea Union Pharm (Edaily Pharm, 22 Aug 2026). On the main board, eleven KOSPI issuers filed non-clean half-year opinions and seventeen KOSDAQ issuers missed the deadline entirely (Ajunews, 19 Aug 2026). The number that matters for methodology is smaller: four . Kainos Medicine, Celestra, EOFlow and Olipass recorded negative total equity at the half-year mark — and under an amended listing rule, half-year negative equity became a listing-eligibility review trigger for the first time, applied to H1 2026 reports. Read that carefully. The companies did not deteriorate in August. Their equity had bee...